EIB and Angelini Ventures' partnership reaches €48.5 million in investments. Rome, 16 September 2026 * New €17 million investment into MMI, a microsurgery robotics company, marks the third investment completed under the €150 million partnership in less than 12 months, following ADCytherix and Nuclidium * A further €20 million has been committed to two additional companies developing new approaches in oncology and rare diseases * Partnership remains on track to invest in 7-10 European companies, with approximately €100 million expected to be invested or committed by early 2027 The European Investment Bank (EIB) and Angelini Ventures, the venture capital firm of Angelini Industries, today announced a €17 million co-investment in MMI, which develops robotic solutions for microsurgery and super-microsurgery, including the Pisa-manufactured Symani system, equipped with the world's smallest articulated robotic instruments. The transaction marks the third investment completed under the partners' €150 million initiative in less than 12 months, highlighting the rapid deployment of capital to breakthrough European life sciences companies. A further €20 million has been committed to two European life sciences companies focused respectively on oncology and rare diseases, with details to be announced following completion of the respective financings. This brings the amount already co-invested by the partnership to €48.5 million, rising to €68.5 million when the two committed investments are included. With five investments either completed or committed, the EIB and Angelini Ventures are making strong progress towards their goal of backing 7 to 10 European companies under the €150 million facility, with approximately €100 million expected to be invested or committed by early 2027. "In less than a year, our partnership with the EIB has already resulted in investments in five European life sciences companies," said Paolo Di Giorgio, CEO of Angelini Ventures. "What stands out is the breadth of innovation behind these companies, from breakthrough medical technologies to new therapeutic approaches. Our focus is on science and technology that can fundamentally change how diseases are treated or care is delivered, and on identifying the companies best positioned to turn that potential into successful businesses. The quality of the opportunities we continue to see makes us very excited about what this partnership can deliver next." "Europe's future competitiveness depends on its ability to turn scientific excellence into global success stories," said EIB Vice-President Gelsomina Vigliotti. "Through our partnership with Angelini Ventures, we are combining capital, expertise and long-term vision to support Europe's most promising healthcare innovators. By helping breakthrough technologies scale and reach patients faster, we are strengthening Europe's innovation ecosystem while delivering tangible benefits for society." The EIB-Angelini Ventures agreement The EIB and Angelini Ventures signed their €150 million co-investment partnership in December 2025, with each committing €75 million over six years to support 7-10 European companies developing innovative solutions across biotechnology, medtech and digital health. The partnership is the first agreement of its kind between the EIB and a corporate venture capital investor in the healthcare sector. The first companies backed through the initiative were ADCytherix, a French biopharmaceutical company developing antibody-drug conjugates (ADCs) for cancer, and Nuclidium, a clinical-stage radiopharmaceutical company developing copper-based radiotheranostics for the diagnosis and treatment of cancer. The EIB and Angelini Ventures co-led an extension of Nuclidium's Series B financing. MMI, a medical technology company developing robotic systems for microsurgery, is the third investment completed under the partnership. The initiative is aligned with TechEU, the EIB Group programme designed to support European innovation and technological leadership. Through TechEU, the EIB Group aims to invest €70 billion in equity, quasi-equity, loans and guarantees between 2025 and 2027, with the ambition of mobilising €250 billion in investment in the real economy. Background information EIB Group The European Investment Bank (EIB) Group is the financing arm of the European Union, owned by the 27 Member States, and one of the largest multilateral development banks in the world. In 2025, the EIB Group signed €100 billion in new financing and advisory services for over 870 high-impact projects under eight core priorities that support EU policy objectives: climate action and the environment, digitalisation and technological innovation, security and defence, territorial cohesion, agriculture and the bioeconomy, social infrastructure, strong global partnerships and the savings and investments union. Beyond long-term loans for large infrastructure, the EIB Group crowds in private investment for high-risk innovative projects and businesses, with a growing role in Europe's markets for venture debt, venture capital, guarantees and securitisations. The European Investment Fund (EIF) is the subsidiary of the EIB Group specialised in providing guarantees, securitisation and equity to improve access to finance for small and medium-sized businesses and startups across Europe. Acting as an anchor investor, through its extensive network of partnering banks and investment funds, the EIF mobilises private investment and nurtures the ecosystem of venture capital funds to support innovative European entrepreneurs. Photos of the EIB Group's representatives and headquarters, logo files and video B-roll for media use are available here. Angelini Ventures is an international venture capital company and part of Angelini Industries, an Italian industrial group working in health, industrial technology and consumer goods. Angelini Ventures was formed in 2022 with planned investments of €300 million, about €150 million of which have already been allocated to startups developing innovative solutions and ideas in biotechnology, medtech and digital health. It invests in innovative companies in Europe and North America that can improve patients' life expectancy and quality of life. The company is based in Rome and has a global team of 25 professionals working in nine cities (Rome, Milan, Turin, London, Singapore, Boston, Berlin, Dubai, Geneva, New York, Munich, Basel and Paris). Angelini Ventures is part of Angelini Industries' strategy to promote innovation by combining existing capabilities and new skills to identify, finance and implement solutions that innovate on traditional healthcare models. Press contacts EIB: Lorenzo Squintani, [email protected], tel.: +39 366 57 90 312 Website: www.eib.org/press Angelini Ventures Martina Palmese, Communications Coordinator - [email protected] SEC Newgate Italia Daniele Pinosa - [email protected] - tel. +39 3357233872 Fausta Tagliarini - [email protected] - tel. +39 3476474513 Daniele Murgia - [email protected] - tel. +39 3384330031 Giulia Cominotti - [email protected] - tel. +39 3391499949 MEDiSTRAVA - Outside Italy Sylvie Berrebi, Sandi Greenwood, Mark Swallow [email protected] Paolo di Giorgio - CEO of Angelini Ventures Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. Healthcare Industry Today do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

NUCLIDIUM's Series B reaches CHF 105 million with latest extension. 29.05.2026 Basel-based biotech NUCLIDIUM has closed an oversubscribed CHF 26 million Series B extension, bringing the round to CHF 105 million, to advance its copper-based cancer diagnostic and therapy programs into expanded Phase 1/2 trials and scale up global manufacturing. NUCLIDIUM develops radiotheranostics - treatments that combine diagnostic imaging and targeted therapy using structurally similar radioactive molecules. The company's approach links tumor-targeting molecules with copper isotopes: Copper-61 for imaging and Copper-67 for therapy. NUCLIDIUM has now closed an oversubscribed CHF 26 million Series B extension, after initially securing CHF 79 million mid-2025, bringing the Series B total raised to CHF 105 million. The financing was led by existing investors Kurma Growth Opportunities Fund, Angelini Ventures, together with EIB co-investment facility Aurea, Wellington Partners and Neva SGR, with participation from DeepTech & Climate Fonds, Bayern Kapital, Vives Partners, NRW.BANK, and additional existing investors. "The Series B extension and support from our world-class investors further validate our strategy to advance next-generation copper-based radiotheranostics and unlock the full potential of the theranostic modality," said Leila Jaafar, CEO and Co-Founder of NUCLIDIUM. The company's lead programs, NU101 in metastatic castration-resistant prostate cancer and NU201 in metastatic breast cancer, have shown superior lesion detection and higher tumor-to-background ratios compared with clinically approved tracers. Both are advancing into expanded Phase 1/2 theranostics trials, supported by the Series B extension. The financing will also support the continued buildout of NUCLIDIUM's worldwide production and manufacturing network for diagnostics and therapeutics, and expand target development for its preclinical programs in additional solid tumor indications. "Radiopharmaceuticals are one of the most compelling growth opportunities in oncology today. NUCLIDIUM has established clear differentiation with its copper-based radiotheranostic approach, demonstrating clinical superiority to competing radioligands and ease-of-use that supports seamless integration into hospital workflow. We are proud to support NUCLIDIUM through this new phase of growth as it advances its pipeline toward additional clinical proof-of-concept data," commented Regina Hodits (Managing Director at Angelini Ventures), Daniel Parera (Partner at Kurma Partners) and Mario Costantini (CEO and General Manager at Neva SGR) on behalf of all participating investors. Photo: Leila Jaafar, CEO and Co-Founder of NUCLIDIUM / Severin Nowacki, Bern 0Comments. More news about.